Table of Content

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview
4.1. Introduction
4.2. Antibody Drug Conjugates Contract Manufacturing Market, by Region

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing outsourcing by biopharmaceutical companies
5.1.1.2. Surging number of CMOs and ongoing R&D activities
5.1.1.3. Growing demand for ADC amid high prevalence of chronic disease
5.1.2. Restraints
5.1.2.1. High cost of setting up a production facility for antibody-drug conjugates
5.1.3. Opportunities
5.1.3.1. Surge in ADC approvals from regulatory bodies
5.1.3.2. Expanding investments in advanced manufacturing technologies
5.1.4. Challenges
5.1.4.1. Stringent regulatory requirements for CMOs
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Antibody Drug Conjugates Contract Manufacturing Market, by Linker
6.1. Introduction
6.2. Cleavable
6.3. Non-cleavable

7. Antibody Drug Conjugates Contract Manufacturing Market, by Condition
7.1. Introduction
7.2. Breast Cancer
7.3. Lymphoma
7.4. Myeloma

8. Antibody Drug Conjugates Contract Manufacturing Market, by End Use
8.1. Introduction
8.2. Clinical Trial
8.3. Myeloma Treatment

9. Americas Antibody Drug Conjugates Contract Manufacturing Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Antibody Drug Conjugates Contract Manufacturing Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Antibody Drug Conjugates Contract Manufacturing Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. AbbVie Inc.
13.1.2. ADC Therapeutics SA.
13.1.3. AstraZeneca PLC
13.1.4. Aurigene Pharmaceutical Services Ltd. by Dr. Reddy’s Laboratories
13.1.5. Axplora
13.1.6. Catalent, Inc.
13.1.7. Creative Biolabs
13.1.8. Daiichi Sankyo
13.1.9. EirGenix, Inc.
13.1.10. Gilead Sciences
13.1.11. GlaxoSmithKline PLC
13.1.12. ImmunoGen, Inc.
13.1.13. Merck KgaA
13.1.14. Mersana Therapeutics
13.1.15. MicroBiopharm Japan Co., Ltd.
13.1.16. Pfizer Inc.
13.1.17. Pierre Fabre S.A
13.1.18. Piramal Pharma Solutions
13.1.19. Recipharm AB
13.1.20. Regeneron Pharmaceuticals, Inc.
13.1.21. Samsung Biologics
13.1.22. Sanofi
13.1.23. Sartorius AG
13.2. Key Product Portfolio

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing



List of Figures

FIGURE 1. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET RESEARCH PROCESS
FIGURE 2. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, 2023 VS 2030
FIGURE 3. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET DYNAMICS
FIGURE 7. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2023 VS 2030 (%)
FIGURE 8. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2023 VS 2030 (%)
FIGURE 10. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2023 VS 2030 (%)
FIGURE 12. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018–2023
TABLE 3. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 6. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CLEAVABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY NON-CLEAVABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 9. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY MYELOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 13. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY MYELOMA TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 16. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 17. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 19. ARGENTINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 20. ARGENTINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 21. ARGENTINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 22. BRAZIL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 23. BRAZIL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 24. BRAZIL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 25. CANADA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 26. CANADA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 27. CANADA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 28. MEXICO ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 29. MEXICO ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 30. MEXICO ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 31. UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 32. UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 35. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 36. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 37. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 38. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 39. AUSTRALIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 40. AUSTRALIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 41. AUSTRALIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 42. CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 43. CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 44. CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 45. INDIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 46. INDIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 47. INDIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 48. INDONESIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 49. INDONESIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 50. INDONESIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 51. JAPAN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 52. JAPAN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 53. JAPAN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 54. MALAYSIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 55. MALAYSIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 56. MALAYSIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 57. PHILIPPINES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 58. PHILIPPINES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 59. PHILIPPINES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 60. SINGAPORE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 61. SINGAPORE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 62. SINGAPORE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 63. SOUTH KOREA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 64. SOUTH KOREA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 65. SOUTH KOREA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 66. TAIWAN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 67. TAIWAN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 68. TAIWAN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 69. THAILAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 70. THAILAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 71. THAILAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 72. VIETNAM ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 73. VIETNAM ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 74. VIETNAM ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 75. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 79. DENMARK ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 80. DENMARK ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 81. DENMARK ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 82. EGYPT ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 83. EGYPT ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 84. EGYPT ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 85. FINLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 86. FINLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 87. FINLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 88. FRANCE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 89. FRANCE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 90. FRANCE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 91. GERMANY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 92. GERMANY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 93. GERMANY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 94. ISRAEL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 95. ISRAEL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 96. ISRAEL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 97. ITALY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 98. ITALY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 99. ITALY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 100. NETHERLANDS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 101. NETHERLANDS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 102. NETHERLANDS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 103. NIGERIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 104. NIGERIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 105. NIGERIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 106. NORWAY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 107. NORWAY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 108. NORWAY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 109. POLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 110. POLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 111. POLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 112. QATAR ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 113. QATAR ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 114. QATAR ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 115. RUSSIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 116. RUSSIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 117. RUSSIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 118. SAUDI ARABIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 119. SAUDI ARABIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 120. SAUDI ARABIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 121. SOUTH AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 122. SOUTH AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 123. SOUTH AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 124. SPAIN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 125. SPAIN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 126. SPAIN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 127. SWEDEN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 128. SWEDEN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 129. SWEDEN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 130. SWITZERLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 131. SWITZERLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 132. SWITZERLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 133. TURKEY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 134. TURKEY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 135. TURKEY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 136. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 137. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 138. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
TABLE 140. UNITED KINGDOM ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 142. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 143. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
TABLE 144. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET LICENSE & PRICING